News Archive of FierceBiotech

ArticleAdded
Senate backs PDUFA for pharma and device reviews 05-24-12
Sangart stashes $50M funding for oxygenation drugs05-24-12
Pharma giants join forces on $285M antibiotics collaboration05-24-12
MediciNova shares crash after lead asthma drug fails IIb trial 05-24-12
Celldex scores upbeat data for breast cancer drug05-24-12
Upstart biotech lures Vertex founder out of retirement05-24-12
J&J loses key FDA panel vote on Xarelto 05-24-12
European pharmas join forces on $285M antibiotics collaboration05-24-12
Sanofi chief highlights high hopes for liver cancer drug05-24-12
Halo garners support for PhII DMD study05-23-12
GSK tweaks Human Genome bid to include poison pill antidote05-23-12
The biggest R&D spenders in biotech05-23-12
Novo confident that it can crack blockbuster oral insulin market 05-23-12
French biotechs afflicted by a plunge in financial support 05-23-12
InterMune deal delivers $55M in fresh fuel for fibrosis drug05-23-12
Pharma VC embrace improves a biotech's chance of success 05-23-12
TheStreet: A roundup of the top drug studies left in 201205-22-12
Study: Countries angling to lure U.S. biopharma companies05-22-12
UPDATED: In rare slap, FDA review rips up Pfizer's case for tafamidis05-22-12
Lilly posts clean safety data on PhIII diabetes blockbuster hopeful05-22-12
Biotechs raise new VC rounds to back inhalable drugs, antimicrobials05-22-12
Takeda shutters Bay Area R&D shop in California shakeup05-22-12
Mohr Davidow's Siegel tapped to run $6B GE health tech initiative05-21-12
New study confirms worst fears about Merck's HIV vaccine05-21-12
Three new rules for biopharma collaborations05-21-12
iPierian salvages new game plan after stem cell tech loses its sizzle 05-21-12
FDA staff backs J&J's Xarelto for heart condition05-21-12
AstraZeneca pulling out all stops in R&D deal frenzy05-21-12
User fee legislation promises better access, speedier reviews at FDA 05-21-12
UPDATED: New cloud hovers over class of 'good cholesterol' drugs 05-18-12
Massachusetts plants seed for new biotech destination 05-18-12
The R&D revolution wants you05-18-12
Cancer Genetics' IPO delayed amid Facebook frenzy05-18-12
Kleiner Perkins to back early-stage biotechs with $525M fund05-18-12
New cloud hovers over class of 'good cholesterol' drugs 05-18-12
Allergan to enlist new hires in R&D expansion05-17-12
Canada hands Osiris historic approval for stem-cell drug05-18-12
Study: FDA outpaces the EMA on drug reviews, new approvals05-17-12
Kythera files $86M IPO to support fat-busting drug05-17-12
HGS faces skeptics as it boasts of a crowded bargaining table05-17-12
UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects05-17-12
GSK lands one-two punch in melanoma trial05-17-12
Piramal bets on pharma's data binging in $635M buyout05-16-12
UPDATED: Upstart Ra sheds stealth status, targets new drug class05-16-12
Cancer drug experts brace for ASCO abstract dump tonight 05-16-12
Elevation boasts 'gold standard' IIb data for COPD therapy05-16-12
Achillion burnishes buyout prospects, snags fast track for hep C drug05-16-12
Ra sheds stealth status, targets HAE with VC cash05-16-12
Genentech drug picked for pioneering $100M Alzheimer's trial05-15-12
Newron soars on positive PhIII results, $26M pact for Parkinson's drug05-15-12
First wave of AstraZeneca's CNS R&D group gets the ax 05-15-12
New chief takes helm at Promedior and steers a course for Boston05-15-12
Buzz: Big Pharma suitors line up for a look at Amylin's books05-15-12
Download our eBook 'Supplying global clinical trials: Keys to avoiding costly delays'05-14-12
GSK snags proteomics platform tech in $98M Cellzome buyout05-15-12
Serono workers plot strike, lash out over R&D failures05-14-12
Lundbeck soars on PhIII success for blockbuster hopeful05-14-12
Cancer drug developers angling for center stage at ASCO05-14-12
OncoMed offers $115M IPO bet on cancer stem cell work 05-14-12
Big Pharma's high-risk pursuit of CNS gold faces major market doubts 05-14-12
FDA panel OKs Gilead's key HIV drug Quad05-11-12
Burrill: Big Pharma's academic tie-ups are 'nuts'05-11-12
Incyte rides wave after Pfizer's FDA panel nod05-11-12
Amgen pushes agenda for biosimilars on the FDA 05-11-12
Indian gov't probes drug regulator after scathing review05-11-12
UPDATED: Arena Pharma's weight drug wins the day, shares soar05-10-12
Google's Brin allies with Pfizer and GSK in war on Parkinson's05-11-12
Arena Pharma's weight drug wins the day05-10-12
Rib-X Pharma delays IPO after price halved05-10-12
All eyes in the biotech world on Arena's diet pill05-10-12
Biotech startup Egalet lassos $14.3M B round, new CEO05-10-12
Subpar clinical trials probed in India's review of regulation05-10-12
Biotech ?gambler? Blech loses big in securities scam05-10-12
UPDATED: FDA advisers sign off on Pfizer's arthritis pill05-09-12
Third Rock's Levin calls for teamwork in personalized medicine05-09-12
Early VC rounds nosedive for biotech startups in Q105-09-12
FDA details kidney damage in Gilead's Quad studies05-09-12
Stem cell therapy rescues child with marrow disease05-09-12
FDA advisers snub Regeneron drug for gout05-09-12
Support seen for U.S. plan to speed nods for 'breakthrough' drugs05-09-12
GSK raises fists in $2.6B hostile bid for Human Genome Sciences05-09-12
FDA withdraws hold on GTx's prostate cancer drug 05-08-12
UPDATED: Arena shares up after FDA briefing on lorcaserin05-08-12
Ex-Sanofi chemist locked up after theft05-08-12
Arena shares up after FDA briefing on lorcaserin05-08-12
Talon sinks after FDA prolongs cancer drug review05-08-12
Amgen, VC groups pump $16.5M into Sutro Biopharma 05-08-12
Eleven adds $20M in venture cash as it preps for the clinic05-08-12
UPDATED: Vertex sizzles with upbeat PhII data on combo therapy for cystic fibrosis05-07-12
Lilly Ventures-backed startup grabs $4.6M round05-07-12
Insmed stock soars after FDA ends hold on key lung drug05-07-12
Novartis passes Phase III test for rare-disorder drug05-07-12
FDA harps on risks of Pfizer's tofacitinib as panel looms05-07-12
Vertex sizzles with upbeat PhII data on combo therapy for cystic fibrosis05-07-12
Roche abandons potential blockbuster cholesterol drug05-07-12
FDA notes cancer cases linked to Regeneron gout drug05-04-12
NIH, U.S. agencies pay for nearly half of global health R&D05-04-12
Bill calls for cancer clinical trials results to be reported--or else05-04-12
Investors pocket $761M in deal betting on Biogen's BG-1205-04-12
FDA whacks Alexza Pharma with CRL for Adasuve05-04-12
Pfizer faces crucial panel vote on blockbuster hopeful tofacitinib05-04-12
Pharma giants offer up drug candidates for $20M NIH collaboration05-03-12
GSK chief rules out AstraZeneca buyout05-03-12
Abbott hits the sweet spot, pays $110M cash for PhIIb drug05-03-12
Crazy or creative? MIT finance whiz suggests a twist on CDOs for R&D05-03-12
Pressure on premiums in M&A push biotech prices higher05-03-12
Idera's troubled TLR program founders in PhII cancer study05-03-12
Lundbeck banks on pipeline as antidepressant sales skid05-02-12
Lilly invests £5.4M in R&D hub in U.K.05-02-12
Aveo Pharma flunks Phase II lung cancer study05-02-12
Pfizer scouts for bite-sized buyouts after Lipitor sales wilt 05-02-12
Savient hammered after hedge fund claims it's bankrupt05-02-12
FDA OK for Gaucher drug opens new market for Pfizer, Protalix05-02-12
Pfizer turns to late-stage pipeline to make up for Lipitor crash05-01-12
Growing Novo Nordisk inks $100M tech deal, boasts of blockbuster hopefuls05-01-12
AstraZeneca's new iMed R&D team forges first pact with Axerion05-01-12
AZ's new iMed R&D team forges first pact with Axerion05-01-12
GSK development team tackles a new drug class at Yale05-01-12
Supernus IPO spotlights perils, potential of going public05-01-12
Brennan's golden handshake could total $65M04-30-12
VC group offers to help axed Merck KGaA staffers launch spinoffs04-30-12
2012: Year of the dealmaker in biopharma04-30-12
Actelion surges as positive PhIII macitentan data reignites buyout buzz 04-30-12
Biotech venture rounds dwindle in Europe, tracking U.S. trend 04-30-12
Vivus gets ED drug approval, spurring fresh talk of a deal 04-27-12
Vivus gets first approval, spurring fresh talk of a deal 04-27-12
UPDATED: Novo Nordisk hiring R&D, other workers in U.S. recruitment blitz04-27-12
Bristol turns to blockbuster pipeline as Plavix goes generic04-27-12
Pfizer stays in the autism drug chase 04-27-12
Astellas, biotech VCs to pump $14M into virtual drug developer04-27-12
Jazz Pharma snaps up Eusa in $700M buyout deal04-27-12
Novo Nordisk hiring R&D, other workers in U.S. recruitment blitz04-27-12
FDA stamps approval on GSK cancer drug Votrient04-27-12
Takeda rebuffed (again) in long quest for FDA drug OK04-26-12
Repligen shares tank on expected FDA rejection04-26-12
PRA snags Amgen's PhIII biosimilars contract04-26-12
Brennan's ouster at AstraZeneca sets stage for big changes in R&D04-26-12
Epizyme builds epigenetics lineup with $90M Celgene score 04-25-12
Buzz: Is Bayer looking to buy Onyx Pharma?04-25-12
Advocacy groups launch new services to match patients and trials04-25-12
GSK and HGS posture over price and value in M&A standoff 04-25-12
Oregano attacks prostate cancer cells in lab experiment04-25-12
Scrambling to add new drugs, Big Pharma is paying big premiums for biotechs04-25-12
The Biggest R&D Spenders in Biopharma04-25-12
Sanofi's Lemtrada beats Rebif in head-to-head MS showdown04-25-12
Targacept slashes staff by half in wake of PhIII disaster04-25-12
Merck KGaA shuttering Swiss complex, dispatching R&D to Boston04-24-12
Amgen founding CEO George Rathmann dies at 8404-24-12
Biogen Idec builds blockbuster case for new MS drug BG-1204-24-12
Argos and miRagen add new venture rounds to back R&D efforts04-24-12
AstraZeneca plots more pipeline deals04-24-12
Merck KGaA shuttering Swiss complex, dispersing R&D staffers to Boston and Beijing04-24-12
Analysts buzz over new Amgen CEO's plans for $20B cache04-24-12
Biota plots U.S. move in Nabi Bio merger04-23-12
PolyMedix shares slide on report of positive Phase II antibiotic data04-23-12
Pike picked to sit at Quintiles peak04-23-12
Buzz: Amylin brings in the bankers to spur an auction04-23-12
AstraZeneca reels in promising Phase III gout drug in $1.26B Ardea buyout04-23-12
Biotech VC deals, dollars shrivel in Q1 as devices see an upturn04-23-12
AstraZeneca reels in promising PhIII gout drug in $1.26B Ardea buyout04-23-12
Alnylam scores efficacy data with PCSK9 drug04-20-12
Lack of Gilead and BMS teamwork on hep C draws ire04-20-12
European committee backs AZ, BMS and Novartis drugs for approval04-20-12
FDA hits brakes on Novartis' hep C program after death04-20-12
Merck KGaA chief swears off major deals amid pipeline woes04-20-12
Readers' picks, responses to Fierce's 'Top 10' cancer drugs report04-20-12
Elan chases a holy grail of Alzheimer's treatment: Prevention 04-19-12
UPDATED: Cell Therapeutics lands myelofibrosis drug with $30M upfront04-19-12
Fox Foundation partners with Sanofi on Parkinson's study04-19-12
Adimab adds Gilead pact to its growing roster of antibody deals04-19-12
Gilead wows analysts as 7977 combos quell hep C in most patients04-19-12
UPDATED: GSK puts Human Genome Sciences in play with $2.59B buyout offer04-19-12
GSK puts Human Genome Sciences in play with $2.59B buyout offer04-19-12
Alder broadens antibody work with $38M D round04-19-12
UPDATED: Crucell and Royal DSM pull the plug on biosimilar JV04-18-12
Abbott touts positive Parkinson's Phase III as pharma split looms04-18-12
Biopharma giants call on FDA to demand tough standards for biosimilars04-18-12
Top 10 late-stage cancer drugs in 201204-18-12
J&J and Bristol-Myers ally on another potential hep C blockbuster04-18-12
10 promising late-stage cancer drugs in 201204-18-12
Roche says it won't extend Illumina offer past Friday deadline04-18-12
GSK doubles down on FivePrime drug discovery collaboration 04-18-12
Crucell and Royal DSM pull the plug on biosimilar JV04-18-12
Addex axes 28 in wake of positive Parkinson's drug study04-17-12
UC San Diego blueprints $110M R&D collaboration complex04-17-12
Aveo on a hiring spree as it preps for the launch of tivozanib04-17-12
Ono's oral MS drug eliminates brain lesions in promising Phase II study 04-17-12
Tech visionary Thiel sets out to spark a biotech revolution04-17-12
Ono's oral MS drug eliminates brain lesions in promising PhII study 04-17-12
Third Rock, biotech VCs make baby formula gambit 04-17-12
Piramal lays claim to a late-stage imaging rival for Lilly's Alzheimer's agent04-16-12
A DIY clinical study? Desperate patients try a therapeutic 'home brew'04-16-12
Halozyme shares plunge on FDA rejection04-16-12
Samsung plans ambitious rollout of biosims at deep discounts04-16-12
Hyperion joins the growing IPO queue with $57M offering04-16-12
Merck snags rights to Endocyte's ovarian cancer drug in $1B deal04-16-12
UPDATED: Sanofi CEO touts partnership drugs as pipeline standouts 04-13-12
Sanofi CEO touts partnership drugs as pipeline standouts 04-13-12
Google VC eyes biotech in data analytics push 04-13-12
UPDATED: Tioga nabs $10M VC deal amid PhIII for bowel disorder drug 04-12-12
Lilly CEO avoids Pfizer-like cuts, focuses on pipeline04-13-12
Embattled AZ chief: Bigger R&D bets, megadeals not the answer04-13-12
UPDATED: Biopharma lobby members pumped $49.5B into R&D04-13-12
Tioga nabs $10M VC deal amid PhIII for bowel disorder drug 04-12-12
Supernus plots product launches as it dusts off $76M IPO attempt04-12-12
NIH chief preps pact to revive shelved drug programs04-12-12
GSK turns to Chiome for antibody discovery04-12-12
Shire picks up Pervasis in potential $200M deal04-12-12
Gilead's blockbuster hep C gamble takes center stage at EASL 04-12-12
Halo takes the virtual approach to developing a DMD treatment04-12-12
Cetero execs look for a silver lining in bankruptcy sale04-11-12
U.K. officials ready $286M fund to fuel a biotech revival04-11-12
Cetero execs look for a silver lining in bankruptcy auction04-11-12
Vertex chief earned $13.4M in '1104-11-12
RNAi developer Arrowhead snags startup Alvos in stock deal04-11-12
Dendreon vets grab the helm of a troubled vaccine developer04-11-12
Threshold Pharma lands $20M milestone from Merck KGaA 04-11-12
Vivus shares slide as FDA delays decision on Qnexa04-10-12
UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout 04-10-12
Affymax banks $50M milestone on ESA drug approval04-10-12
Amgen snags KAI Pharma's CKD program in $315M buyout 04-10-12
Merck, Flagship join forces on fostering biotech startups04-10-12
Icahn sues Amylin in hopes a proxy fight will trigger sale 04-10-12
H.I.G. unveils a $268M fund dedicated to biotech04-09-12
FT: AstraZeneca investors turn up the heat under CEO Brennan04-09-12
Analysts pounce on positive Phase II data on hep C combo04-09-12
Optimer ousts chairman, top execs over a grant of shares in affiliate04-09-12
Novartis researchers discover promising arthritis molecule 04-09-12
Lilly gains FDA approval for its controversial brain plaque test04-09-12
Bristol stays in hunt for Amylin04-06-12
Astellas scores FDA panel nod for overactive bladder drug04-06-12
Time for a three-day weekend04-05-12
Biocon hiring 300 scientists for new R&D complex in India04-05-12
Cleveland BioLabs shares tank after BARDA drops support04-05-12
Biotech vets back $22M A round for neuroscience startup04-05-12
Sanofi colorectal cancer contender Zaltrap suffers a PhIII trial setback04-05-12
Spectrum nabs Allos buyout as bladder cancer drug fails PhIII 04-05-12
Industry Voices: The Fibrosis Stampede04-04-12
Biogen Idec bets it can succeed on a risky Phase III ALS gamble 04-04-12
Abbott wows the crowd with promising Phase II hep C data04-04-12
Icahn goes in for the kill at Amylin04-04-12
Nanomedicine standout spotlights first human cancer data04-04-12
Biogen Idec bets it can succeed on a risky PhIII ALS gamble 04-04-12
Billions in new venture cash targeted at early-stage biotech efforts04-04-12
AstraZeneca scouts new drug deals to silence a chorus of critics04-04-12
OvaScience grabs $37M B round for fertility treatments04-03-12
Traditional Chinese medicine team preps for Phase II cancer study04-03-12
High-profile investigator tapped to lead $10M prostate cancer program04-03-12
Stemline bets $50M IPO on a pair of cancer stem cell treatments04-03-12
Google contributes to $14M round for fast-growing Adimab04-03-12
Bayer bolsters blockbuster case for regorafenib with new PhIII data04-03-12
UPDATED: AstraZeneca pays $50M to partner up on Amgen antibodies04-02-12
AstraZeneca pays $50M to partner up on Amgen antibodies04-02-12
Keryx, Aeterna shares crater on word of Phase III cancer study flop04-02-12
AstraZeneca pays $50 million to partner up on Amgen antibodies04-02-12
Novartis posts promising Phase III results for blockbuster hopeful QVA149 04-02-12
Lundbeckfond contributes to $25M B round for AlloCure's Phase II stem cell study04-02-12
GSK's Witty calls for joint effort on antibiotic development04-02-12
UPDATED: Roche readies for approvals of previously snubbed breast cancer drug03-30-12
Merrimack Pharma stumbles out of the IPO gate03-30-12
PhIII failure blights Shire's effort to crack new market for bowel drug03-30-12
FDA panel favors added cardio studies for risky weight drugs03-30-12
Ex-Amgen drug researcher calls out questionable cancer findings 03-30-12
Provenge critic gaining attention after taking shots at study data03-30-12
Keryx, Aeterna shares crater on word of Phase III cancer study failure04-02-12
Tokai unveils promising Phase I data for 'triple whammy' prostate cancer contender04-02-12
Check out the new and improved FierceBiotech.com03-30-12
AVI tanks after positive PhIIb fails to improve outcomes for DMD 04-02-12
UPDATED: FDA rejects Chelsea's Northera, demands additional study data03-28-12
Optimer inks $90M C. difficile drug pact with Astellas03-29-12
Amgen, Lilly turn in upbeat data on rival psoriasis drugs03-29-12
Cetero preps for new owner after filing for bankruptcy protection03-29-12
Is an Amylin takeover inevitable after the BMS rejection? 03-29-12
VC boom: U.K. charity births $80M biotech fund for cancer drug research03-29-12
FDA rejects Chelsea's Northera, demands additional study data03-28-12
Merrimack Pharma discounts expectations in $100M IPO03-28-12
Moscow backs clones of Western biotech programs in Russia03-28-12
UPDATED: Amylin shares rocket up on report of $3.5B buyout offer by Bristol-Myers03-28-12
Promethera Biosciences banks $31M to fund PhI/II stem cell trial03-28-12
Novartis leads $12.5M A round for antibody diagnostics start-up ImaginAb03-28-12
Amylin shares rocket up on report of $3.5B buyout offer by Bristol-Myers03-28-12
Conflicting signals cloud Chelsea's chances on D-Day for Northera03-28-12
Affymax breaks Amgen's anemia drug monopoly with ESA approval03-27-12
Lawmakers push for speedy approvals of 'breakthrough' drugs03-27-12
Biogen executive team rakes in millions from its 2011 successes03-27-12
Targacept scuttles diabetes drug program in fresh setback03-27-12
Bausch & Lomb snags experimental eye treatments in $500M ISTA buyout03-27-12
UPDATED: FDA stiff-arms Map's app for migraine therapy Levadex03-27-12
Tesaro promises rapid progress with cancer drugs in $86M IPO03-26-12
Sanofi, Regeneron report stellar LDL drug data as race heats up 03-26-12
Fierce's Top 10 Biotech techies03-26-12
FDA accusations of 'corrupt' lab practices push Cetero into bankruptcy 03-26-12
Amgen CEO's retirement pay could register at $49M03-26-12
Bleeding risk clouds Merck's hopes for vorapaxar franchise03-26-12
FDA accusations of "corrupt" lab practices push Cetero into bankruptcy 03-26-12
Private equity player pumping $50M into cancer drug startup03-26-12
Amgen's LDL blockbuster hopeful wows with impressive efficacy data 03-25-12
UPDATED: GSK, Theravance share mixed bag of lung drug data ahead of FDA filing03-23-12
Durata, with license to Pfizer drug, lays plans for $86M IPO03-23-12
Merck backs big VC plan in Canada03-23-12
Depression drug research goes off the rails (again)03-23-12
UPDATED: Addex surges on upbeat data from Parkinson's drug trial03-23-12
$110M therapeutics center on tap for UC San Diego campus03-23-12
GSK, Theravance share mixed bag of lung drug data ahead of FDA filing03-23-12
Addex surges on upbeat data from Parkinson's drug trial03-23-12
UPDATED: Merck drug homes in on new baldness target03-22-12
Pozen shares jump on promising outcome for PhIII studies03-22-12
Pozen shares jump on promising outcome for Ph3 studies03-22-12
Merck drug homes in on new baldness target03-22-12
Developers spotlight huge potential of new class of cholesterol drugs03-22-12
Big Pharma entry's new name, AbbVie: rhymes with R&D 03-22-12
Growing popularity of virtual biotechs promises boon to outsourcers03-22-12
New drug for rare leukemia wins FDA panel vote with limited data03-22-12
A rare leukemia drug wins FDA panel vote with limited data03-22-12
UPDATED: Cytos revives lead program in $40M financing deal with Amgen, venBio03-21-12
J&J unit to pay $8.7M to Galapagos for drug candidate03-21-12
NicOx eyes global status in eye drug game with up to $30.9M buyout of Altacor03-21-12
Amarin jumps on positive patent news for blockbuster hopeful03-21-12
NicOx eyes global status in eye drug game with up to $30.9M buyout of Altcor03-21-12
FDA panel shoots down Merck/Ariad cancer drug as GSK marches on03-21-12
Cytos revives lead program in $40M financing deal with Amgen, venBio03-21-12
GSK, J&J back Index's new $200M fund for early-stage deals03-21-12
Pfizer faces bumps in road with potential blockbuster RA pill 03-20-12
Nektar boosts R&D presence in San Francisco03-20-12
New $317M biotech fund takes off at Wellcome Trust03-20-12
U.K. green lights study of pioneering gene therapy against cystic fibrosis03-20-12
Shire snaps up CNS program from startup Heptares, commits $190M in 'biobucks' 03-20-12
Virtual is beautiful in biotech03-20-12
Final PhIII results wipe out AstraZeneca, Targacept depression drug 03-20-12
Final Ph3 results wipe out AstraZeneca, Targacept depression drug 03-20-12
Ampio Pharma shares soar after upbeat update on eye drug03-19-12
VC dollars flowing into Europe03-19-12
Cardiome whips out budget ax as Merck dumps oral heart drug pact03-19-12
Roche headlines autism alliance03-19-12
Anthera slashes jobs over failed cardiac trial, shifts focus to lupus drug03-19-12
At the threshold of PhIII, Neurologix heads into bankruptcy03-19-12
Don't let the past obscure your future03-19-12
Amarin stock jumps on patent progress for blockbuster hopeful; OncoGenex seeks $46.8M in stock sale;03-16-12
Novartis grabs rights to eye drug in $494M deal03-16-12
Sanofi beefs up former Genzyme unit with Pluromed buyout03-16-12
After slashing jobs, Pfizer CEO Ian Read draws $25M03-16-12
FDA questions benefit of Merck and Ariad's bone cancer drug 03-16-12
VCs rally behind Tarsa Therapeutics in $28M B round03-16-12
Active Biotech gets boost from late-stage oral MS program03-16-12
Shire yanks BLA for Fabry treatment in surprise about-face 03-15-12
Biogen Idec strikes $34M option pact with MAKScientific03-15-12
UPDATED: Merck offers $90M to bankroll new drug discovery institute03-15-12
Sofinnova preps Irish venture plans with $37.5M in fresh support03-15-12
Merck offers $90M to bankroll new drug discovery institute03-15-12
Did Big Pharma scuttle an attempt to radically restructure the approval pathway?03-15-12
Shire nabs Bay Area's FerroKin, orphan drug in $325M buyout03-15-12
Your name here: Max Planck Florida shops naming rights for $10M03-14-12
Okairos launches pioneering mid-stage study of promising hep C vaccine03-14-12
Marina inks $14M discovery pact with ProNAi 03-14-12
Animal rights groups in U.K. blockade supply routes for researchers03-14-12
Langer upstart rakes in fresh venture cash for mucus-targeting drugs03-14-12
Sir Chris Evans inspires creation of a £100M Welsh biotech fund 03-14-12
Omeros touts promising PhIII for ophthalmology treatment03-13-12
Regulators start thinking creatively about new approval pathway03-13-12
NicOx spikes on successful glaucoma drug study03-13-12
FDA scientists see improved integrity, but complaints of interference still common03-13-12
FDA panel backs effort to lift class hold on anti-NGF pain drugs03-13-12
Pfizer walks away from $350M insulin pact with India's Biocon03-13-12
Disappointing cancer data triggers sharp drop in Peregrine shares03-12-12
Bionovo slashes bulk of staff, cuts costs as cash runs out03-12-12
HemaQuest nails $13M VC extension for sickle cell program03-12-12
Bionovo slashes bulk of staff, cuts costs on cash crunch03-12-12
Pfizer spearheads push to get pain drugs back on blockbuster track03-12-12
Tranzyme shares implode as lead GI drug flunks its PhIII closeup03-12-12
Anthera shares collapse on halt of Phase III cardio trial03-12-12
Anthera shares collapse on halt of Ph3 cardio trial03-12-12
UPDATED: Teva, OncoGenex amp up Phase III fight against prostate cancer03-09-12
FDA nudged to treat antibiotics like rare disease drugs03-09-12
AstraZeneca nears bundle of buyouts to feed ailing pipeline03-09-12
Aastrom banks $38M for pivotal study of cellular therapy03-09-12
Teva, OncoGenex amp up Phase III fight against prostate cancer03-09-12
Big trouble seen for targeted cancer drugs03-09-12
Merck cancer drug digs into HIV's last hiding places03-09-12
'Dateline' exposé snares Indian CROs in an ethics 'sting'03-08-12
Bellicum snags $20M for mid-stage cancer vaccine program03-08-12
Gilead spotlights key details from pivotal Quad study 03-08-12
J&J wows analysts with early success of Zytiga PhIII for prostate cancer03-08-12
NeurogesX slashes staff, shifts R&D direction after FDA slaps down app03-08-12
J&J wows analysts with early success of Zytiga Ph3 for prostate cancer03-08-12
Promedior lands $21.5M D round for fibrosis pipeline03-07-12
CNS drug developers face long stretch in the clinic, poor odds of success03-07-12
Positive Phase III sets stage for levomilnacipran NDA03-07-12
Fresh woes for Gilead as two more hep C patients relapse in small 7977 study03-07-12
Mersana snaps up $270M cancer drug deal with Endo Pharma03-07-12
Tufts: CNS drug developers face long stretch in the clinic, poor odds of success03-07-12
Discovery Labs shares rocket up on long-awaited FDA approval03-07-12
OpGen bags up to $17M in VC deal03-07-12
UPDATED: Aragon raises $42M for closely-watched prostate cancer drug03-05-12
Abcam's $155M Epitomics buyout expands antibody business 03-06-12
Our collaboration with BioWorld Today03-06-12
Top 10 VC medical device deals H2 201103-06-12
Aegerion application for lead rare disease drug lands at FDA03-06-12
Oncothyreon shares routed as Stimuvax PhIII trial soldiers on03-06-12
Domain partners with RusNano on $760M biotech investment plan 03-06-12
Aragon raises $42M for closely-watched prostate cancer drug03-05-12
Company 'insiders' left with 43% of Verastem's shares03-05-12
PhIII placebo response complicates Lundbeck's case for anti-drinking drug 03-05-12
Merck plans NDA on promising Phase III data for allergy pill03-05-12
FDA rejects Merck's new combo cholesterol drug03-05-12
SciClone dumps cancer drug after failed IIb03-05-12
FDA rejects Merck's new combo cholesterol drug03-05-12
Fledgling 4s3 garners $20M for rare disease work03-05-12
Company 'insiders' nabbed 43% of Verastem's IPO offering03-05-12
High Ph3 placebo response complicates Lundbeck's case for anti-drinking drug 03-05-12
Roche arthritis drug beats Humira in clinical study03-02-12
Gov't advisor calls on FDA to boost clinical trials of drugs in kids03-02-12
Ex-Amgen R&D chief Perlmutter in talks with other companies about next move03-02-12
Columbia Labs axing 42% of jobs after FDA shoots down drug application03-02-12
Bioethicist quits job at controversial stem cell outfit 03-02-12
Novartis cancer drugs stymie deadly Ebola virus03-02-12
GSK and Daiichi create joint development venture in Japan03-01-12
Key to IPO success: recruiting 'insiders' who will buy into the offering03-01-12
Pfizer, BMS face a delay on FDA's megablockbuster decision on apixaban 03-01-12
Parkinson's drug combats disability after major brain injuries03-01-12
Elan CEO puts retirement party on hold as Alzheimer's PhIII looms03-01-12
GSK and Daiichi create new vaccine joint development venture in Japan03-01-12
Elan CEO puts retirement party on hold as Alzheimer's PhIII looms03-01-12
Dutch antibody experts forge rare disease discovery pact with Shire02-29-12
C3 Jian raises $30M for dental treatment02-29-12
Vivus basks in limelight of rampant M&A speculation 02-29-12
Abbott's deal-team delivers $1.35B Galapagos RA pact 02-29-12
Dainippon bags Boston Biomedical and cancer stem cell tech in $2.6B buyout02-29-12
Concert Pharma snags $200M licensing pact with Avanir02-29-12
Forest, Gedeon trumpet fresh Phase III successes for antipsychotic pill02-28-12
Can an herbal medicine provide the key to defeating Alzheimer's?02-28-12
Bayer CEO Dekkers says price cuts threaten R&D02-28-12
The dream of human immortality tonics lives on--in worms02-28-12
BMS amps up academic partnerships with PhII project at Duke02-28-12
Biogen Idec races to FDA and EMA with a blockbuster app for BG-1202-28-12
Shanghai-based CRO Newsummit outlines $80M IPO02-27-12
BioSante shares surge on GVAX data for pancreatic cancer02-27-12
GSK lassos rare disease program in Angiochem tie-up02-26-12
Merck KGaA triggers restructuring as it pursues R&D turnaround 02-27-12
Study finds no (unique) industry bias in published trial results02-27-12
FDA rejects Columbia Labs' gel to prevent preterm births02-27-12
GSK lassos rare disease program in Angiochem tie up02-26-12
GSK steps in to back Canadian vaccine project02-24-12
Biotech VC climate warmer than some thought02-24-12
Swiss biotech Actelion grabs rights to biologic in $68.5M deal02-24-12
Russian biotech VC and Quintiles to join forces on pharma services startups02-24-12
Forest Labs notches victory en route to FDA ruling on COPD drug02-24-12
Chelsea Therapeutics surges on FDA panel nod for Northera02-24-12
I'd like to add you to my professional network02-24-12
$100M Russian biotech fund opens shop in Boston02-23-12
New Zelboraf data shows big survival boost02-23-12
Sanofi slams doors on Genzyme's Cambridge, U.K., outfit02-23-12
UPDATE: Vivus soars after experts offer surprising support for weight drug02-22-12
Vertex vows to race ahead with interferon-free combo for hep C02-23-12
Satori snags $15M to fuel a trial on Alzheimer's drug02-23-12
UPDATED: FDA panel overwhelmingly backs Vivus' diet drug02-22-12
FDA panel overwhelmingly backs Vivus' diet drug02-22-12
Genomics revolution ignites new M&A talk, showstoppers02-22-12
Eisai co-developing cancer drug fueled by bacteria; U.S. trials launch soon 02-22-12
Collegium Pharma scores $22M round for abuse-preventing painkiller in Phase III02-22-12
Venture backer makes $7M bet on cardio drug tech that could rival stents02-22-12
Biotech VCs wait for big checks from string of buyout deals02-22-12
Lee Hood startup grabs $10M to advance class of protein-capture agents02-22-12
Pfizer amps up R&D partnering activity in China and India02-21-12
Novartis snags preclinical hep C drug in $440M Enanta pact02-21-12
FDA staffers advise agency to deny Chelsea's key drug02-21-12
FDA raises cardio concerns on Forest's new COPD drug02-21-12
Threshold shares spike on positive IIb data for pancreatic cancer drug02-21-12
GTx shares tumble after clot threat forces hold on prostate cancer drug02-21-12
Corcept skyrockets on FDA nod for rare disease drug02-17-12
UPDATED: Gilead disappoints with relapse data in oral Hep C study02-17-12
Vivo Ventures boosting biopharma bets in China with $375M fund02-17-12
Observing Presidents Day02-17-12
Pfizer grabs leg up in pursuit of rare disease drug win02-17-12
Senator launches campaign for speedier approvals of targeted drugs02-17-12
MIT scientists tout first human data on drug-delivery chips02-17-12
FDA notes concerns about Vivus diet pill safety ahead of panel02-17-12
Gilead disappoints with relapse data in oral Hep C study02-17-12
Patent attorneys gear up as new biosimilar rules impact IP strategies02-16-12
Sanofi's Viehbacher spotlights Big Pharma's new role creating biotechs02-16-12
Alnylam identifies who's getting ax02-16-12
J&J backs potential pain drugs derived from spider venom02-16-12
Biotech startup Mnemosyne snags $5.4M A round for neuropsych R&D02-16-12
Bionor surges as PhIIb study revives big hopes for HIV vaccine02-16-12
Severino tapped to helm Amgen's global development team02-15-12
Teva looks set for a new round of M&A deals02-15-12
Tiny Atossa designs micro IPO to fund breast cancer work02-15-12
Corporate VCs crowd into $43M round for Celladon02-15-12
Hep C drug deal frenzy can't be slowed by growing doubts02-15-12
Battered BioSante soars on FDA approval for testosterone gel02-15-12
Pfizer R&D chief talks up chances for late-stage Alzheimer's drug02-14-12
InnaVirVax nabs $4.9M in B round to advance HIV immunotherapy 02-14-12
Actelion hunts for answers about 120 deaths in key drug trial 02-14-12
Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix02-14-12
Karo Bio walks away from Phase III cholesterol drug due to safety risks 02-14-12
Pioneering stem cell therapy mends damaged heart tissue in patients 02-14-12
The best of times, the worst of times?02-14-12
DNA sequencing exposes new uses for Pfizer targeted cancer drugs02-13-12
Chelsea shares nosedive on FDA's questions about key drug 02-13-12
GSK studies Chinese remedies to discover new drugs 02-13-12
Preclinical study triggers 'massive response' from desperate Alzheimer's patients02-13-12